What is the partnership between Noxopharm (ASX:NOX) and Novotech about?

Noxopharm has engaged Novotech, a global clinical research organisation (CRO), to lead its regulatory strategy in the United States. Novotech will provide specialist advice to help Noxopharm prepare a data package for a formal meeting with the US Food & Drug Administration.

Why is the pre-IND meeting with the FDA important for Noxopharm (ASX:NOX)?

A pre-IND meeting allows a biotech company to get direct feedback from the FDA on its planned clinical trials, preclinical studies, and manufacturing controls. Securing this feedback early helps Noxopharm de-risk the development process by ensuring their data meets US regulatory standards.

What is SOF-SKN™ and what market is it targeting?

SOF-SKN™ is a drug candidate developed on Noxopharm's Sofra™ technology platform, designed to treat chronic inflammation caused by the autoimmune disease cutaneous lupus erythematosus.

How does the Novotech engagement affect the Noxopharm (ASX:NOX) investment thesis?

This engagement signals that management is pivoting from early research toward formal regulatory and commercial milestones in the world's largest pharmaceutical market.

What are the potential long-term applications of Noxopharm’s Sofra™ platform?

While SOF-SKN™ is the immediate priority, the underlying Sofra™ technology platform has broader potential beyond skin-related autoimmune diseases. Management believes the platform could eventually be utilised for large-market conditions such as rheumatoid arthritis, psoriasis, and diabetes.

What are the main bull points for Noxopharm (ASX:NOX) after this news?

The primary bull case is that Noxopharm is professionalising its US entry by hiring an experienced CRO to navigate the complex FDA environment. Success in the pre-IND stage could lead to a partnership or licensing deal with a larger pharmaceutical company.

Noxopharm engages Novotech for US regulatory strategy

Written by Brie CarterPublished May. 5 2026Last Updated May. 5 2026

Noxopharm (ASX:NOX) announced the engagement of Novotech, a globally recognised clinical research organisation, to spearhead its US regulatory strategy.

The partnership is designed to facilitate a critical pre-Investigational New Drug meeting with the US Food & Drug Administration regarding Noxopharm’s lead asset, SOF-SKN.

The collaboration aims to refine the clinical development pathway and ensure the robustness of the data package required for a subsequent full IND application.

The pre-IND stage is a vital milestone in the pharmaceutical sector, allowing companies to receive direct feedback from the FDA on preclinical study designs and manufacturing quality controls.

By securing this engagement, Noxopharm intends to boost the commercial attractiveness of SOF-SKN to potential industry partners in the United States and global markets.

SOF-SKN is currently being developed to treat the autoimmune disease cutaneous lupus erythematosus, a market valued at over US$3.3 billion and projected for significant expansion.

Noxopharm CEO Dr Olivier Laczka emphasised that this step demonstrates the genuine potential of the broader Sofra technology platform, which may eventually address other conditions like psoriasis, rheumatoid arthritis, and diabetes.

"Boosting SOF-SKN’s attractiveness in the market is a top priority," Dr Laczka stated, noting that the engagement with Novotech streamlines the complex regulatory journey ahead.